Wechselwirkungen · Harvoni
Harvoni 90 mg/400 mg film-coated tablets Harvoni 45 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-132252 · Präparat HOS-097208
15 Medicinal product by Effects on medicinal Recommendation concerning co-administration therapeutic areas product levels. with Harvoni Mean ratio (90% confidence interval) for AUC, Cmax, Cmina, b Lopinavir boosted with Interaction not studied. When given with lopinavir/ritonavir used in ritonavir + emtricitabine/ Expected: conjunction with tenofovir disoproxil fumarate, tenofovir disoproxil ↑ Lopinavir Harvoni is expected to increase the concentration of fumarate ↑ Ritonavir tenofovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage 9809b38b1302f940e5379a7d8ea572b57a13aa39e4360c2a8a29707e8f7aa766 · Zeichen 25740–26494 im Abschnitt